Trial Profile
A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Ferric carboxymaltose (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms GeparOcto
- 17 Nov 2021 Results assessing survival data, time-to-event secondary end-points of the GeparOcto trial, published in the European Journal of Cancer.
- 21 Sep 2020 Results assessing invasive disease-free survival and overall survival, presented at the 45th European Society for Medical Oncology Congress.
- 04 Jun 2019 Results (n=914) assessing pathologic complete response (pCR) rates according to germline mutation status in patients from this study, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.